Nazia J. Khan

Nazia Khan is an associate in the Corporate Practice Group in the firm's Washington D.C. office.

Areas of Practice

Nazia’s practice focuses on corporate finance and securities laws. She represents companies and underwriters in public and private corporate finance transactions, including initial public offerings, shelf registrations, registered direct transactions, private investments in public equity (PIPEs), private placements and other securities offerings.

In addition, Nazia represents publicly held companies with their reporting obligations under the Exchange Act and with NASDAQ, NYSE and other exchange listing and compliance matters including matters involving FINRA.

Experience

• Represented Greenwich LifeSciences, Inc. in its initial public offering and listing on Nasdaq
• Represented Majesco in sale to private equity firm for $729 million.
• Represented Hoth Therapeutics, Inc. in its initial public offering and listing on Nasdaq
• Represented Immuron Limited in its initial public offering and listing on Nasdaq
• Represented Aridis Pharmaceuticals, Inc., in its initial public offering and listing on Nasdaq
• Represented underwriters in an initial public offering and listing on Nasdaq of a company in the rideshare industry
• Represented underwriters in an initial public offering of and listing on Nasdaq of a biotechnology company focused on early cancer screening and detection

Honors

New York Metro Rising Stars, Super Lawyers, 2017-2020

Ones to Watch — Corporate Law, Best Lawyers, 2021, 2022

Who's Who in America, 2019

Articles

Corporate and Securities Law Blog Posts

• "SEC Amends Definitions of “Accelerated Filer” and “Large Accelerated Filer” and Provides Relief to Small Issuers from Auditor Attestation Requirements," March 18, 2020

• "SEC Administrative Proceedings Against Public Companies for Failure to Remediate Material Weaknesses in Internal Control Over Financial Reporting," February 5, 2019 
• "Expansion of Regulation A to Reporting Companies: Increased Alternatives Now Available to Public Companies Seeking to Raise Capital or for Mergers and Acquisitions," February 1, 2019
• "The Effects of the SEC Shutdown on the Capital Markets," January 18, 2019
• "SEC Expands the Definition of 'Smaller Reporting Company,'" July 12, 2018

Cannabis Law Blog Posts

• "FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products," March 9, 2020

Media Mentions